Stereotaxis (NYSEAMERICAN:STXS) Trading Down 2.2% – Here’s What Happened

Stereotaxis, Inc. (NYSEAMERICAN:STXS) traded down 2.2% during trading on Thursday . The stock traded as low as $2.18 and last traded at $2.19. 271,151 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 306,758 shares. The stock had previously closed at $2.24.

Stereotaxis Stock Down 2.2 %

The firm has a market capitalization of $185.56 million, a P/E ratio of -7.82 and a beta of 1.57.

Stereotaxis (NYSEAMERICAN:STXS) last released its earnings results on Monday, November 11th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $9.20 million for the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 162.54%. On average, equities research analysts expect that Stereotaxis, Inc. will post -0.26 EPS for the current fiscal year.

Institutional Trading of Stereotaxis

A number of hedge funds have recently modified their holdings of STXS. Vanguard Group Inc. raised its stake in shares of Stereotaxis by 7.7% in the first quarter. Vanguard Group Inc. now owns 2,613,966 shares of the company’s stock valued at $6,822,000 after purchasing an additional 187,437 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Stereotaxis by 247.5% during the second quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company’s stock worth $345,000 after buying an additional 135,041 shares in the last quarter. SG Americas Securities LLC bought a new stake in Stereotaxis in the 3rd quarter valued at $39,000. Renaissance Technologies LLC raised its stake in shares of Stereotaxis by 46.2% in the 2nd quarter. Renaissance Technologies LLC now owns 488,700 shares of the company’s stock valued at $889,000 after buying an additional 154,400 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Stereotaxis by 645.6% during the 2nd quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock worth $88,000 after acquiring an additional 41,780 shares during the period. Institutional investors own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.